These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20634541)

  • 21. Nanomaterials and the environment: uses, methods and measurement.
    Carl Englert B
    J Environ Monit; 2007 Nov; 9(11):1154-61. PubMed ID: 17968441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomaterial health effects--Part 2: Uncertainties and recommendations for the future.
    Powell MC; Kanarek MS
    WMJ; 2006 May; 105(3):18-23. PubMed ID: 16749320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Greener nanoscience: a proactive approach to advancing applications and reducing implications of nanotechnology.
    Hutchison JE
    ACS Nano; 2008 Mar; 2(3):395-402. PubMed ID: 19206562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays.
    Kroll A; Dierker C; Rommel C; Hahn D; Wohlleben W; Schulze-Isfort C; Göbbert C; Voetz M; Hardinghaus F; Schnekenburger J
    Part Fibre Toxicol; 2011 Feb; 8():9. PubMed ID: 21345205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of nanomaterials for toxicity assessment.
    Sayes CM; Warheit DB
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(6):660-70. PubMed ID: 20049823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
    Hirose A; Nishimura T; Kanno J
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotoxicology and nanomedicine: making hard decisions.
    Linkov I; Satterstrom FK; Corey LM
    Nanomedicine; 2008 Jun; 4(2):167-71. PubMed ID: 18329962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro assessments of nanomaterial toxicity.
    Jones CF; Grainger DW
    Adv Drug Deliv Rev; 2009 Jun; 61(6):438-56. PubMed ID: 19383522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging in vitro models for safety screening of high-volume production nanomaterials under environmentally relevant exposure conditions.
    Kathawala MH; Xiong S; Richards M; Ng KW; George S; Loo SC
    Small; 2013 May; 9(9-10):1504-20. PubMed ID: 23019115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The protein-nanomaterial interface.
    Asuri P; Bale SS; Karajanagi SS; Kane RS
    Curr Opin Biotechnol; 2006 Dec; 17(6):562-8. PubMed ID: 17015011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomaterial health effects part 3: conclusion--hazardous issues and the precautionary principle.
    Kanarek MS
    WMJ; 2007 Feb; 106(1):16-9. PubMed ID: 17393752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular interactions of nanomaterials and organisms: defining biomarkers for toxicity and high-throughput screening using traditional and next-generation sequencing approaches.
    Klaper R; Arndt D; Bozich J; Dominguez G
    Analyst; 2014 Mar; 139(5):882-95. PubMed ID: 24343342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research strategies for safety evaluation of nanomaterials, part VIII: International efforts to develop risk-based safety evaluations for nanomaterials.
    Thomas K; Aguar P; Kawasaki H; Morris J; Nakanishi J; Savage N
    Toxicol Sci; 2006 Jul; 92(1):23-32. PubMed ID: 16687392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and characterization of engineered nanoparticles in food and the environment.
    Tiede K; Boxall AB; Tear SP; Lewis J; David H; Hassellov M
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2008 Jul; 25(7):795-821. PubMed ID: 18569000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative in vitro assays in nanomaterial toxicology.
    Hartung T; Sabbioni E
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(6):545-73. PubMed ID: 21766468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomaterials for in situ cell delivery and tissue regeneration.
    Wan AC; Ying JY
    Adv Drug Deliv Rev; 2010 Jun; 62(7-8):731-40. PubMed ID: 20156499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicology of engineered nanomaterials - introduction.
    Wiegand HJ; Krüger N; Norppa H; Carmichael N; Greim H; Vrijhof H
    Toxicol Lett; 2009 May; 186(3):147. PubMed ID: 19118608
    [No Abstract]   [Full Text] [Related]  

  • 40. Embryo-fetal developmental toxicity study design for pharmaceuticals.
    Wise LD; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Lerman SA; Ooshima Y; Stump DG
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):418-28. PubMed ID: 20025038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.